口服瘤治疗药物和心血管风险管理和监测
Raechel T White1, Marie E Sirek2, Joel C Marrs3
1University of New Mexico College of Pharmacy, Albuquerque, NM.
Journal of cardiovascular pharmacology
|July 27, 2023
概括
口服瘤治疗需要仔细评估和监测心血管风险. 本综述强调在癌症治疗期间和之后管理潜在的心脏副作用,以确保患者的安全.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 口服瘤治疗方法已经进步,增加了对心血管疾病 (CV) 管理的需求.
- 某些口服抗瘤药物可以引起不良心血管事件,包括左心室功能障碍,高胆固醇血症,高血压和心律失常.
研究的目的:
- 在开始口服抗瘤药物治疗之前,审查对心血管风险的评估.
- 突出治疗期间和治疗后监测和管理心血管不良事件的方法.
- 评估癌症患者的传统心血管风险因素.
主要方法:
- 对当前的指导方针和建议进行文献审查.
- 分析与癌症发展和进展相关的心血管风险因素.
- 讨论管理心脏毒性的多学科团队方法.
主要成果:
- 在治疗前进行心血管风险评估对于接受口服抗瘤治疗的患者至关重要.
- 在整个治疗过程中,需要对心血管不良事件进行持续监测.
- 管理策略应侧重于尽量减少心血管损伤和以患者为中心的决策.
结论:
- 积极主动和多学科的方法对于管理与口服瘤治疗相关的心血管毒性至关重要.
- 将心脏瘤学原则纳入癌症护理,可以改善患者的治疗结果.
- 仔细监测患者和量身定制的治疗选择是减轻心血管风险的关键.
相关概念视频
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
Coronary Artery Disease IV: Preventive Measures
24
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
24
Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
Cardiomyopathy VI: Nursing Management
13
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
13
Cardiomyopathy VII: Pre and Post Operative Nursing Management
16
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
16
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
206
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
206


